Outcomes of 68Ga-NODAGA-Exendin-4 PET/CT Guided Surgical Management of Insulinomas in MEN1: A Preliminary Study
Nuklearmedizin - NuclearMedicine · 01.10.2025 · 64 (05) · 301-307
DOI: 10.1055/a-2694-8248 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.10.2025. Verfasst von Ketki Sunil Ambulkar und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Seth GS Medical College and KEM Hospital, Maharashtra, India. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Insulinoma, Multiple Endocrine Neoplasia Type 1, Exenatide. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
The data on the use of 68Ga-NODAGA-exendin-4 PET/CT in localizing multiple endocrine neoplasia type 1 (MEN1)-related insulinomas is evolving; however, surgical outcomes data are not available. We describe our cohort of patients with MEN1-related endogenous hyperinsulinemic hypoglycemia (EHH), where 68Ga-NODAGA-exendin-4 PET/CT was used to guide conservative surgery. A retrospective record review of MEN1-related EHH cases managed between 2000 and 2024 was performed for clinical features, imaging, and management. Outcomes were assessed for patients whose surgical extent was determined by 68Ga-NODAGA-exendin-4 PET/CT versus conventional imaging (CECT and 68Ga-DOTATATE PET/CT). Five patients with a median age of 17 (15.5–18.5 years) with EHH underwent laparoscopic, single lesion enucleation based on 68Ga-NODAGA-exendin-4 PET/CT. On preoperative imaging, CT identified culprit lesion in four, while 68Ga-DOTATATE PET/CT localized in one, and had one false positive uptake in non-functioning NET. The median duration of hospital stay was 6 (5.5–9) days. Over a median follow-up of 48 (3.5–84.5) months, none had EHH recurrence or exocrine/endocrine pancreatic insufficiency. On follow-up, one patient had an uneventful pregnancy and delivery. In the remaining 15, who underwent surgery based on conventional imaging, 12 (80 %) required extensive surgery beyond enucleation, of which two needed intraoperative ultrasound localization. This group had a postoperative hospital stay of 11 (8–23) days, one recurrence after 84 months, and pancreatic insufficiency in 5 (33 %). Our center observation suggests that GLP1R-based PET/CT-guided conservative insulinoma surgery in MEN1 patients is effective and safe and needs further validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Seth GS Medical College and KEM Hospital, Maharashtra, India.
- Harikrushna Hormone Clinic, Anand, India.
- Department of Endocrinology, Vydehi Institute of Medical Sciences and Research Centre, Bangalore, India.
- Department of General Surgery, Seth GS Medical College and KEM Hospital, Mumbai, India.
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Mumbai, India.
- Department of Nuclear Medicine, Jaslok Hospital & Research Center, Nagpur, India.
ORCID-Profile: Tushar Bandgar
Zitieren
APA
Ambulkar, K. S., Shah, R., Lila, A., Sharma, A., Barnabas, R., Karlekar, M., Memon, S. S., Sarathi, V., Rege, S., Verma, P., Malhotra, G., Lele, V., & Bandgar, T. (2025). Outcomes of 68Ga-NODAGA-Exendin-4 PET/CT Guided Surgical Management of Insulinomas in MEN1: A Preliminary Study. Nuklearmedizin - NuclearMedicine, 64(05), 301-307. https://doi.org/10.1055/a-2694-8248
Vancouver
Ambulkar KS, Shah R, Lila A, Sharma A, Barnabas R, Karlekar M, et al. Outcomes of 68Ga-NODAGA-Exendin-4 PET/CT Guided Surgical Management of Insulinomas in MEN1: A Preliminary Study. Nuklearmedizin - NuclearMedicine. 2025;64(05):301-307. doi:10.1055/a-2694-8248
BibTeX
@article{Ambulkar2025,
author = {Ambulkar, Ketki Sunil and Shah, Ravikumar and Lila, Anurag and Sharma, Anima and Barnabas, Rohit and Karlekar, Manjiri and Memon, Saba Samad and Sarathi, Vijaya and Rege, Sameer and Verma, Priyanka and Malhotra, Gaurav and Lele, Vikram and Bandgar, Tushar},
title = {Outcomes of 68Ga-NODAGA-Exendin-4 PET/CT Guided Surgical Management of Insulinomas in MEN1: A Preliminary Study},
journal = {Nuklearmedizin - NuclearMedicine},
year = {2025},
volume = {64},
number = {05},
pages = {301--307},
doi = {10.1055/a-2694-8248}
}
EUVIMED